Starling Oncology, Inc. furnished an updated investor presentation as Exhibit 99.1 to be used in upcoming meetings with investors. This filing is an amendment (Form 8-K/A) that supersedes a previous version of the presentation filed earlier the same day.
Starling Oncology, Inc. has prepared a formal investor presentation to be used in upcoming meetings with investors. The presentation, dated November 12, 2026, was furnished as an exhibit to the 8-K filing and includes a discussion of the company's strategy and financial trends.
Starling Oncology Insider Jorey Chernett Sells $11.4M of Stock
Jorey Chernett sold 2,851,061 shares of Starling Oncology, Inc. at $3.99 a share, worth $11.4M in total on Nov 6, 2026. Shares held after the trade: 7,809,797 (-26.7%).
Starling Oncology Insider Jorey Chernett Buys $176K of Stock
Jorey Chernett bought 48,294 shares of Starling Oncology, Inc. at $3.65 a share, worth $176K in total on Nov 9, 2026. Shares held after the trade: 7,858,091 (+0.6%).
Starling Oncology, Inc. reported a significant revenue increase to $478.5 million for the nine months ended September 30, 2026, driven primarily by growth in its Specialty Pharmacy segment. Despite this growth, the company remains unprofitable with a net loss of $28.0 million for the period and a total stockholders' deficit of $37.4 million.
Starling Oncology reported Q3 2026 consolidated revenue of $169.8 million, a 24.3% increase year-over-year, and achieved its second consecutive quarter of positive Adjusted EBITDA at $3.4 million. The company updated its full-year 2026 revenue guidance to $650-$660 million and raised the low end of its Adjusted EBITDA outlook to $4-$6 million.
Term
Q3 2026
“The third quarter of 2026 was another strong quarter for our company, with revenue up 24% year over year and Adjusted EBITDA of $3.4 million, our second consecutive quarter of positive Adjusted EBITDA and above our third quarter outlook of $0.50 million to $1.5 million. Our capitated business continues to deliver growth, with capitated revenue up 40% and MLR performing at expectations. Our Specialty pharmacy business grew 44% year over year, with strong gross margins of 24% for this segment. Starling Nexus, our proprietary provider-focused portal, is now live and available to our network clinicians to support care coordination and evidence-based care on our delegated capitation model. Based on our performance year to date, we are affirming our full-year 2026 guidance, and we believe we are well positioned for continued growth into 2027.”